Labor Commissioner Gary Molloy told senators that the territory’s labor force participation rate is under 50 percent, though ...

Paul Hickey, Bespoke Co-Founder, Sarah Bianchi, Evercore ISI Chief Strategist, and Douglas Boneparth, Bone Fide Wealth President, discuss AI, rates, China, oil and stocks. Got a confidential news tip?

The Microsoft Outlook outage that left thousands unable to use the email service is finally over. It began as the work week started. Downdetector, which tracks outages and problems for online ...

"We're closely monitoring the health of the service environment amidst our ongoing recovery work, and we're observing some sections of affected infrastructure which aren't accepting the re-applied ...

Snow day? Microsoft on Monday confirmed a widespread, multi-hour outage affecting Outlook users, leading to email delays and failures, authentication issues, and other problems. In a post on X, ...

Access to Microsoft Outlook appears to be mostly restored after thousands of users reported issues using the platform on Monday, Aug. 31. However, hundreds still seem to be having issues as of Tuesday ...

Microsoft has started rolling out a Classic Outlook theme for users of Outlook on the web and the New Outlook for Windows. This new Outlook theme is rolling out as part of a targeted release beginning ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Outlook Therapeutics stock has been through a very rough stretch over the past ...

FDA approves first bevacizumab formulation for wet AMD, but Outlook's stock drops 37% monthly amid negative equity and commercial launch concerns. The US Food and Drug Administration has finally ...

Morning call sheet: Microsoft leads as tech earnings reshape market outlook Jay Woods, Chief Market Strategist at Freedom Capital Markets, Steve Grasso, CEO of Grasso Global, and Patrick Moorhead, CEO ...

FDA decision on ONS-5010 for wet AMD looms as Outlook Therapeutics secures SEC clearance for warrant share sales and boosts authorized shares to 600M amid $50.9M liabilities. Outlook Therapeutics ...